Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations
Cardiology Journal · 2024
DOI: 10.5603/cj.93062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology Journal, 2024. Verfasst von Kongyong Cui und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sc…. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Drug-Eluting Stents. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Lipoprotein(a) [Lp(a)] was positively associated with recurrent ischemic events in patients with acute coronary syndrome (ACS). This study was performed to investigate the effect of Lp(a) levels on outcomes of dual antiplatelet therapy (DAPT) > 1 year versus DAPT ≤ 1 year after percutaneous coronary intervention (PCI) in this population.
Methods
A total of 4,357 ACS patients who were event-free at 1 year after PCI were selected from the Fuwai PCI Registry, and patients were stratified into four groups according to DAPT duration (≤ 1 year vs. > 1 year) and Lp(a) levels (≤ 30 mg/dL vs. > 30 mg/dL). The primary endpoint was major adverse cardiovascular and cerebrovascular event (MACCE), defined as a composite of cardiac death, myocardial infarction or stroke.
Results
After 2.4-year follow-up, the incidence of MACCE (HRadjusted 0.284, 95% CI 0.115–0.700; HRIPTW 0.351, 95% CI 0.164–0.751) were significantly reduced in DAPT > 1 year group than that in DAPT ≤ 1 year group in individuals with elevated Lp(a) levels. However, in individuals with normal Lp(a) levels, no statistically difference was found between these two groups in terms of MACCE, although the risks of all-cause death and definite/probable stent thrombosis were lower in DAPT > 1 year group. Notably, the risk of clinically relevant bleeding did not statistically differ between these two groups in individuals with different Lp(a) levels.
Conclusions
This study firstly demonstrated that extended DAPT (> 1 year) was statistically associated with lower risk of ischemic events in ACS patients with elevated Lp(a) levels after PCI, whereas this association was not found in individuals with normal Lp(a) levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- State Key Laboratory of Cardiovascular Disease, Beijing, China.
- National Clinical Research Center for Cardiovascular Diseases, Beijing, China.
- Department of Cardiology, Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. drdoukefei@12…
- State Key Laboratory of Cardiovascular Disease, Beijing, China. drdoukefei@126.com.
- National Clinical Research Center for Cardiovascular Diseases, Beijing, China. drdoukefei@126.com.
ORCID-Profile: Kongyong Cui
Zitieren
APA
Cui, K., Wu, S., Yin, D., Song, W., Wang, H., Zhu, C., Feng, L., Yang, Y., Fu, R., & Dou, K. (2024). Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations. Cardiology Journal. https://doi.org/10.5603/cj.93062
Vancouver
Cui K, Wu S, Yin D, Song W, Wang H, Zhu C, et al. Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations. Cardiology Journal. 2024. doi:10.5603/cj.93062
BibTeX
@article{Cui2024,
author = {Cui, Kongyong and Wu, Shaoyu and Yin, Dong and Song, Weihua and Wang, Hongjian and Zhu, Chenggang and Feng, Lei and Yang, Yuejin and Fu, Rui and Dou, Kefei},
title = {Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations},
journal = {Cardiology Journal},
year = {2024},
doi = {10.5603/cj.93062}
}
EUVIMED